Literature DB >> 20381452

Long-term culture following ES-like gene-induced reprogramming elicits an aggressive phenotype in mutated cholangiocellular carcinoma cells.

Ken-ichi Nagai1, Hideshi Ishii, Norikatsu Miyoshi, Hiromitsu Hoshino, Toshiyuki Saito, Tetsuya Sato, Yoshito Tomimaru, Shogo Kobayashi, Hiroaki Nagano, Mitsugu Sekimoto, Yuichiro Doki, Masaki Mori.   

Abstract

BACKGROUND: We recently reported that gastrointestinal (GI) cancer cells can be reprogrammed to a pluripotent state by the ectopic expression of defined embryonic stem (ES)-like transcriptional factors. The induced pluripotent cancer (iPC) cells from GI cancer were sensitized to chemotherapeutic agents and differentiation-inducing treatment during a short-term culture, although a phenotype induced by long-term culture needs to be studied.
METHODS: A long-term cultured (Lc)-iPC cells were produced in GI cancer cell lines by virus-mediated introduction of four ES-like genes-c-MYC, SOX2, OCT3/4, and KLF4-followed by a culture more than three months after iPC cells induction. An acquired state was studied by expression of immature-related surface antigens, Tra-1-60, Tra-1-81, Tra-2-49, and Ssea-4; and epigenetic trimethyl modification at lysine 4 of histone H3. Sensitivity to chemotherapeutic agents and tumorigenicity were studied in Lc-iPC cells.
RESULTS: Whereas the introduction of defined factors of iPC cells once induced an immature state and sensitized cells to therapeutic reagents, the endogenous expression of the ES-like genes except for activated endogenous c-MYC was down-regulated in a long-term culture, suggesting a high magnitude of the reprogramming induction by defined factors and the requirement of therapeutic maintenance in Lc-iPC cells from cholangiocellular carcinoma HuCC-T1 cells, which harbor TP53(R175H) and KRAS(G12D). The Lc-iPC cells showed resistance to 5-fluorouracil in culture, and high tumorigenic ability with activated endogenous c-MYC in immunodeficient mice.
CONCLUSION: The Lc-iPC cells from HuCC-T1 might be prone to an undesirable therapeutic response because of an association with the activated endogenous c-MYC. To consider the possible therapeutic approach in GI cancer, it would be necessary to develop a predictive method for evaluating the improper reprogramming-associated aggressive phenotype of iPC cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20381452     DOI: 10.1016/j.bbrc.2010.03.176

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

1.  A highly optimized protocol for reprogramming cancer cells to pluripotency using nonviral plasmid vectors.

Authors:  Hongzhi Zhao; Timothy J Davies; Jiaolin Ning; Yanxu Chang; Patty Sachamitr; Susanne Sattler; Paul J Fairchild; Fang-Ping Huang
Journal:  Cell Reprogram       Date:  2014-12-30       Impact factor: 1.987

Review 2.  Constructing and Deconstructing Cancers using Human Pluripotent Stem Cells and Organoids.

Authors:  Ryan C Smith; Viviane Tabar
Journal:  Cell Stem Cell       Date:  2018-12-20       Impact factor: 24.633

Review 3.  Reprogramming of gastrointestinal cancer cells.

Authors:  DyahLaksmi Dewi; Hideshi Ishii; Naotsugu Haraguchi; Shimpei Nishikawa; Yoshihiro Kano; Takahito Fukusumi; Katsuya Ohta; Susumu Miyazaki; Miyuki Ozaki; Daisuke Sakai; Taroh Satoh; Hiroaki Nagano; Yuichiro Doki; Masaki Mori
Journal:  Cancer Sci       Date:  2012-01-17       Impact factor: 6.716

4.  Generation of induced pluripotent stem cells from mouse cancer cells.

Authors:  Frances Ka-Yin Lin; Yiu-Loon Chui
Journal:  Cancer Biother Radiopharm       Date:  2012-08-14       Impact factor: 3.099

Review 5.  Induced pluripotent cancer cells: progress and application.

Authors:  Chun Sun; Yin Kun Liu
Journal:  J Cancer Res Clin Oncol       Date:  2010-11-26       Impact factor: 4.553

6.  Generation and characterization of virus-free reprogrammed melanoma cells by the piggyBac transposon.

Authors:  Juan Yin; Yongna Fan; Dingxin Qin; Xiaocui Xiaocui Bian; Xiaobao Bi
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-10       Impact factor: 4.553

Review 7.  Eradication of therapy-resistant cancer cells in gastrointestinal organs.

Authors:  Shimpei Nishikawa; Masamitsu Konno; Atsushi Hamabe; Shinichiro Hasegawa; Hisataka Ogawa; Yoshihiro Kano; Takahito Fukusumi; Katsuya Ohta; Yuko Noguchi; Miyuki Ozaki; Toshihiro Kudo; Daisuke Sakai; Naotsugu Haraguchi; Taroh Satoh; Yuichiro Doki; Masaki Mori; Hideshi Ishii
Journal:  Mol Clin Oncol       Date:  2012-08-20

8.  HMGA1 reprograms somatic cells into pluripotent stem cells by inducing stem cell transcriptional networks.

Authors:  Sandeep N Shah; Candace Kerr; Leslie Cope; Elias Zambidis; Cyndi Liu; Joelle Hillion; Amy Belton; David L Huso; Linda M S Resar
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

9.  Generation of Induced Pluripotent Stem (iPS) Cells by Nuclear Reprogramming.

Authors:  Dilip Dey; Gregory R D Evans
Journal:  Stem Cells Int       Date:  2011-10-05       Impact factor: 5.443

10.  Effect of in vivo administration of reprogramming factors in the mouse liver.

Authors:  Akira Tomokuni; Hidetoshi Eguchi; Hiromitsu Hoshino; Dyah Laksmi Dewi; Shinpei Nishikawa; Yoshihiro Kano; Norikatsu Miyoshi; Arinobu Tojo; Seiichiro Kobayashi; Noriko Gotoh; Kunihiko Hinohara; Noemi Fusaki; Toshiyuki Saito; Hiroshi Suemizu; Hiroshi Wada; Shogo Kobayashi; Shigeru Marubashi; Masahiro Tanemura; Yuichiro Doki; Masaki Mori; Hideshi Ishii; Hiroaki Nagano
Journal:  Oncol Lett       Date:  2013-06-20       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.